Biosyngen Approved for US Trials of TCR-T Candidate for Solid Tumor Cancers
publication date: Sep 11, 2023
Biosyngen, a Singapore-Guangzhou cell therapy company, was green-lighted to begin a US Phase I/II clinical trial of its first T-cell receptor-engineered targeted (TCR-T) product for lung cancer, gastric cancer and other advanced solid tumors. The approval for BRL03 is the company's third first-in-class therapy and its first self-developed candidate to start clinical trials. Biosyngen is currently filing an IND application for BST02, a tumor-infiltrating lymphocyte (TIL) molecule. When BRL03 is approved, the company will have clinical-stage assets in all three major T-cell therapy types -- CAR-T, TCR-T and TIL. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.